Pharmaceutical Technology2h
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Intellia Therapeutics’ Strategic Reorganization and Promising Clinical Progress Justify Buy Rating
Leerink Partners analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) on January 10 and set a price ...
Here are 71 Mass. life science firms presenting at J.P. Morgan
Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...
The Pharma Letter21h
The week in pharma: action, reaction and insight – week to January 10
Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...
Strategic Shift and Uncertainties Lead to Hold Rating for Repare Therapeutics
Bloom Burton analyst David Martin PhD has maintained their neutral stance on RPTX stock, giving a Hold rating on January 10.Stay Ahead of the ...